An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema

ALN-F12 dose-dependent reduction of circulating FXII in female cynomolgus monkeys. Female cynomolgus monkeys were subcutaneously administered a single dose of ALN-F12 (n = 3 per group). Plasma FXII levels were measured by ELISA and normalized to the average of individual animal's pre-dose average of Days −5, −3, and −1 (error bars = SD). Panel A represents the relative plasma FXII level on Day 28 post-dosing; Panel B depicts the relative FXII levels at all collected time points for all dosing groups.